Use of Remdesivir in children with COVID-19: report of an Italian multicenter study.

Lorenza RomaniMarco RoversiStefania BernardiElisabetta VenturiniSilvia GarazzinoDaniele DonàAndrzej KrzysztofiakCarlotta MontagnaniElisa FunicielloFrancesca Ippolita Calò CarducciCaterina MarabottoElio CastagnolaFilippo SalviniLaura LancellaAndrea Lo VecchioLuisa GalliGuido Castelli Gattinaranull null

Published in: Italian journal of pediatrics (2024)

Our experience indicates that RDV against SARS-CoV-2 is safe and well-tolerated in pediatric populations at high risk of developing severe COVID-19. Our data suggest that delaying RDV therapy after diagnosis of pneumonia may be associated with a longer duration of antiviral therapy, especially in patients with comorbidities.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
young adults
early onset
electronic health record
stem cells
intensive care unit
big data
bone marrow
drug induced
smoking cessation